Ceptaris Therapeutics, Inc. Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel  
1/18/2012 6:52:10 AM

MALVERN, Pa.--(BUSINESS WIRE)--Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris’ investigational drug, chlormethine gel (also known as mechlorethamine gel in the US), for the treatment of Cutaneous T-Cell Lymphoma (CTCL).